Kibow Therapeutics Presents Phase 2b Results for KT-301 at ASN Kidney Week 2026
News related to:Kibow Therapeutics · 2 min read
EXTON, Pa., Oct. 21, 2026 /CourierPR/ -- Kibow Therapeutics, a clinical-stage biotechnology company based in the United States, is set to present groundbreaking research at the American Society of Nephrology (ASN) Kidney Week 2026, taking place from October 21 to 25 in Denver, Colorado. The company's Chief Medical Officer, Robert Segal, MD, FACP, will present the results of a Phase 2b study of KT-301, a proprietary live biotherapeutic, in patients with Stage 4 chronic kidney disease (CKD). This study, involving 327 participants, aims to explore whether modulating the gut microbiome can slow the progression of late-stage kidney disease.
The study is part of Kibow Therapeutics' ongoing commitment to advancing scientific research and developing new therapeutic approaches for people living with kidney disease.
In addition to the clinical trial results, Kibow Therapeutics will also present new mechanistic research. Usha Vyas, Ph.D., Vice President of Research and Development at Kibow Therapeutics, will present a scientific poster examining the effects of KT-301 on the gut microbiome using advanced laboratory models. MDT.
Kibow Therapeutics, founded in 1997, has spent nearly three decades pioneering research into the relationship between the intestinal microbiome and kidney function. The company's work has helped advance understanding of how gut bacteria, the metabolism of waste compounds, and inflammation may influence kidney health. KT-301, the company's lead investigational therapy, targets uremic toxins associated with CKD and is being evaluated for its potential to slow disease progression and improve quality of life.
The company's participation in ASN Kidney Week reflects its ongoing commitment to rigorous scientific investigation and collaboration with the broader nephrology research community. By presenting these findings, Kibow Therapeutics aims to contribute to the advancement of treatment options for patients with chronic kidney disease.
Founded in 1997, Kibow Therapeutics has been at the forefront of research into the gut-kidney connection. Its work has helped advance understanding of how gut bacteria, the metabolism of waste compounds, and inflammation may influence kidney health. KT-301, the company's lead investigational therapy, targets uremic toxins associated with CKD and is being evaluated for its potential to slow disease progression and improve quality of life. The Phase 2b study, involving 327 patients, is part of a larger effort to develop innovative live biotherapeutics for people with chronic kidney disease.
The Phase 2b study is designed to assess whether modulating the gut microbiome with a kidney-specific synbiotic can slow the progression of Stage 4 CKD. This potentially novel therapeutic strategy addresses a significant unmet need for patients with advanced kidney disease.
Usha Vyas, Ph.D., Vice President of Research and Development at Kibow Therapeutics, will present a scientific poster examining the effects of KT-301 on the gut microbiome using advanced laboratory models. The research explores the interaction between targeted probiotics, intestinal microbial activity, and factors associated with CKD. This mechanistic study complements the clinical trial results and provides deeper insights into the potential mechanisms of action of KT-301.
Kibow Therapeutics' participation in ASN Kidney Week is a testament to its commitment to advancing scientific research and developing new therapeutic approaches for people living with kidney disease. By presenting these findings, the company aims to contribute to the broader understanding of the gut-kidney connection and the potential of microbiome-based therapies in managing chronic kidney disease.